Sanofi shies away from neuro gene therapy programs

Changes to two partnerships this year suggest Sanofi is paring down the disease areas in which it wants to deploy gene therapy.

The latest came on Monday, when Voyager Therapeutics Inc. (NASDAQ:VYGR) said it and Sanofi (Euronext:SAN; NASDAQ:SNY) agreed to terminate Sanofi's ex-U.S. option rights to

Read the full 450 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE